Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.

CONCLUSION: Based on PLATO trial data, one-year treatment with ticagrelor versus generic clopidogrel in patients with ACS, relative to WHO reference standards, is cost-effective from a Singapore public healthcare perspective. PMID: 23546032 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/23546032?dopt=Abstract

Source: Singapore Medical Journal - March 1, 2013 Category: Journals (General) Authors: Chin CT, Mellstrom C, Chua TS, Matchar DB Tags: Singapore Med J Source Type: research